Search

Displaying results 7701 - 7710 of 10000 in total
  1. Drug

    Dexfosfoserine

    go.drugbank.com/drugs/DB04522
    Investigational

    The phosphoric acid ester of serine.

  2. Drug

    SAR421869

    go.drugbank.com/drugs/DB17909
    Investigational

    SAR421869 is a Lentiviral Vector Containing The Human My07A Gene currently being investigated for the treatment of retinitis pigmentosa associated with Usher syndrome 1B gene defect.

  3. Drug

    AZD2315

    go.drugbank.com/drugs/DB06540
    Experimental

    The drug AZD2315, an immunosuppressant developed by AstraZeneca, was in Phase 1 clinical trials for the treatment of rheumatoid arthritis but was discontinued during this phase

  4. Drug

    Porphobilinogen

    go.drugbank.com/drugs/DB02272
    Experimental

    It is generated by the enzyme ALA dehydratase, and converted into hydroxymethyl bilane by the enzyme porphobilinogen deaminase.

  5. Drug

    BT200

    go.drugbank.com/drugs/DB18333
    Investigational

    [A261491] It is under investigation for the treatment of von Willebrand disease and hemophilia A.[L48156] … BT200 (Rondoraptivon pegol) is a PEGylated anti-von Willebrand factor (VWF) aptamer targeted against the VWF A1 domain.

  6. Drug

    BGT-DTDS

    go.drugbank.com/drugs/DB18664
    Experimental

    It is under investigation for the treatment of dopamine transporter deficiency syndrome (DTDS). … BGT-DTDS is an investigational gene therapy comprising an adeno-associated viral vector type 2 (AAV2) encoding the human _SLC6A3_ gene.

    Synonyms: Adeno-associated viral vector serotype 2 containing the human SLC6A3 gene
  7. Drug

    Cry5B

    go.drugbank.com/drugs/DB17783
    Experimental

    Cry5B is a pore-forming crystal protein produced by and derived from the soil bacterium _Bacillus thuringiensis_. … With demonstrated anthelmintic properties, it has been investigated in the treatment of parasitic intestinal infections.[A259372, A259377]

  8. Drug

    2X-121

    go.drugbank.com/drugs/DB16063
    Investigational

    2X-121 is under investigation in clinical trial NCT03562832 (Investigation of Anti-tumour Effect and Tolerability of the PARP Inhibitor 2X-121 in Patients With Metastatic Breast Cancer Selected by the

  9. Drug

    Sonepcizumab

    go.drugbank.com/drugs/DB06305
    Investigational

    S1P is the extracellular ligand for the G protein-coupled lysophospholipid receptor EDG-1 (endothelial differentiation gene-1). … Upon administration, sonepcizumab binds S1P, which may result in the inhibition of tumor angiogenesis.

  10. Drug

    Tasurgratinib

    go.drugbank.com/drugs/DB21222
    Investigational

    The usage of the INN stem '-gratinib' in the name indicates that Tasurgratinib is a fibroblast growth factor receptor (FGFR) inhibitor.

    Synonyms: E 7090